Sasaki S, Gando S, Kobayashi S, Nanzaki S, Ushitani T, Morimoto Y, Demmotsu O
Division of Intensive Care, Hokkaido University Hospital, Sapporo, Japan.
ASAIO J. 2001 Jan-Feb;47(1):86-91. doi: 10.1097/00002480-200101000-00018.
We performed this study to identify predictors of mortality in critically ill patients treated with continuous venovenous hemodiafiltration (CVVHDF) for acute renal failure in an intensive care setting. It was an uncontrolled, observational study that took place in a general intensive care unit in a university hospital. Forty-one patients undergoing CVVHDF for acute renal failure in a consecutive sample of 1,018 ICU treatments were studied. The underlying disease included 25 postsurgical cases and 16 medical cases. Between survivors (n = 23) and nonsurvivors (n = 18), the following factors were assessed: demographic data; the number and type of failed organs; Acute Physiology and Chronic Health Evaluation (APACHE) II scores; urine production; pH; base excess; serum creatinine levels; bilirubin levels; lactate levels; platelet counts; and hemodynamic variables, including cardiac index and central venous pressure. On univariate analyses, the number of failed organs (p < 0.01), presence of hepatic failure (p < 0.01), APACHE II scores (p < 0.01), pH (p < 0.01), base excess (p < 0.001), average urinary production before the initiation of CVVHDF (p < 0.05), and serum bilirubin (p < 0.01) and lactate levels (p < 0.001) were significantly different. Multiple regression analysis identified serum bilirubin (p < 0.01) and lactate levels (p < 0.01) as the predictors of hospital mortality. Presence of hepatic failure was also predictive of hospital mortality (p < 0.01) in the analysis of the type of organ failure. The cut-off value set at bilirubin levels > 10 mg/dl or arterial lactate levels > 3.5 mmol/L provided 83.3% sensitivity and 90.9% specificity in the prediction of hospital death. The crucial factors in predicting outcome of critically ill patients undergoing CVVHDF for renal failure are elevated serum bilirubin and lactate levels at the onset of CVVHDF. Presence of hepatic failure, defined as both jaundice and coagulopathy, may also worsen outcome of critically ill patients undergoing CVVHDF for renal failure. The cut-off value set at bilirubin levels > 10 mg/dl or arterial lactate levels > 3.5 mmol/L may serve as beneficial predictors of hospital mortality.
我们开展这项研究,旨在确定在重症监护环境下接受连续性静脉-静脉血液透析滤过(CVVHDF)治疗急性肾衰竭的重症患者的死亡预测因素。这是一项在大学医院的普通重症监护病房进行的非对照观察性研究。在1018例ICU治疗的连续样本中,对41例因急性肾衰竭接受CVVHDF治疗的患者进行了研究。基础疾病包括25例术后病例和16例内科病例。在幸存者(n = 23)和非幸存者(n = 18)之间,评估了以下因素:人口统计学数据;衰竭器官的数量和类型;急性生理与慢性健康状况评估(APACHE)II评分;尿量;pH值;碱剩余;血清肌酐水平;胆红素水平;乳酸水平;血小板计数;以及血流动力学变量,包括心脏指数和中心静脉压。单因素分析显示,衰竭器官数量(p < 0.01)、肝衰竭的存在(p < 0.01)、APACHE II评分(p < 0.01)、pH值(p < 0.01)、碱剩余(p < 0.001)、CVVHDF开始前的平均尿量(p < 0.05)、血清胆红素(p < 0.01)和乳酸水平(p < 0.001)存在显著差异。多因素回归分析确定血清胆红素(p < 0.01)和乳酸水平(p < 0.01)为医院死亡率的预测因素。在器官衰竭类型分析中,肝衰竭的存在也可预测医院死亡率(p < 0.01)。设定胆红素水平> 10 mg/dl或动脉乳酸水平> 3.5 mmol/L的临界值,在预测医院死亡方面具有83.3%的敏感性和90.9%的特异性。预测接受CVVHDF治疗肾衰竭的重症患者预后的关键因素是CVVHDF开始时血清胆红素和乳酸水平升高。定义为黄疸和凝血障碍的肝衰竭的存在,也可能使接受CVVHDF治疗肾衰竭的重症患者的预后恶化。设定胆红素水平> 10 mg/dl或动脉乳酸水平> 3.5 mmol/L的临界值可作为医院死亡率的有益预测指标。